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So Much Soma

Satvir Dhillon, MD; Gregory Shimizu, MD

Internal Medicine Residency – Riverside Community Hospital / UC Riverside School of Medicine

Introduction

Discussion

Withdrawal from the medication carisoprodol (Soma) is
not as well described in the literature compared to other
substances, so physicians may be less familiar with the
presentation. This case illustrates a rare presentation of
carisoprodol withdrawal.

Carisoprodol is a centrally acting skeletal
muscle relaxant. It has been recognized to
have a high potential for abuse leading to
tolerance, dependence, and withdrawal
symptoms with prolonged use. This led the
Drug Enforcement Agency to classify
carisoprodol as a Schedule IV controlled
substance in 2012. Despite this, the diversion
and abuse of carisoprodol has continued to
be prevalent. The recommended maximum
duration of use is up to two to three weeks.
Abrupt cessation after prolonged use can
lead to withdrawal symptoms. Typical
withdrawal symptoms associated with
carisoprodol dependency include abdominal
cramps, nausea, headache, insomnia,
irritability, and anxiety. Symptoms typically
peak at anywhere from 36 to 48 hours, and
major symptoms last for approximately
3 days. An uncommonly reported withdrawal
symptom is carisoprodol withdrawal induced
psychosis as seen in this patient. Studies have
highlighted the role of meprobamate, a
metabolite of carisoprodol, in the production
of withdrawal symptoms. Meprobamate
belongs to the class of sedative, hypnotic, or
anxiolytic medications. Treatment is typically
with brief courses of benzodiazepines, and
antipsychotic agents have been used to
manage psychotic symptoms.

Case description
A 56-year-old female with hypertension,
chronic kidney disease, and fibromyalgia was
brought to the emergency room by her
roommate with an acute change in
personality and paranoia. Two days prior, the
roommate reported the patient was acting
“giddy.” The following day she became
withdrawn and paranoid. While patient was
uncooperative with history, her friend denied
any psychiatric or substance abuse history.
Patient was hypertensive, otherwise her vitals
were within normal range. Exam was
significant for poor eye contact,
inattentiveness, bizarre behavior, visual and
auditory hallucinations, disorganized though
process, and poor insight and judgement.
Abnormal labs included a leukocytosis and an
elevated creatinine. Her urine toxicology
screen and blood alcohol level were negative.
CT brain did not show evidence of acute
intracranial abnormality.

Figure 1. Chemical structure of
meprobamate and carisoprodol

Case description

Further history was obtained revealing the
patient had been taking three 350mg tablets
of carisoprodol at bedtime for ten years for
relief of pain due to fibromyalgia. Three days
prior to admission, she abruptly stopped
taking the carisoprodol due to unavailability
of the medication. The patient was placed on
lorazepam as needed for agitation. She
continued to be intermittently agitated and
combative until two days after admission
when her symptoms improved and patient
returned to her baseline.
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